The Congressional Research Service (CRS) has issued a report titled “Compounded Drugs” to address the risks and oversight issues raised by the growing volume of drugs produced through nontraditional compounding— that is, outside the context of a pharmacist creating a prescription in consultation with a licensed health provider to treat a specific patient. Among other matters, the report examines the 2012 fungal meningitis outbreak traced to a compounding pharmacy, recent recalls, information about the compounded drugs currently produced, who is producing them, and information on adverse events. CRS prepared the report in response to policymaker questions about how best to ensure the safety of compounded drugs given the traditional state role in regulating pharmacies and the lack of any federal requirements for adverse event reporting in this sector.
Register now for your free, tailored, daily legal newsfeed service.
Questions? Please contact firstname.lastname@example.orgRegister
CRS issues report on compounded drugs
Popular articles from this firm
If you would like to learn how Lexology can drive your content marketing strategy forward, please email email@example.com.
Related topic hubs
Privacy Manager, Global Privacy Centre
"This is a very good resource and I appreciate receiving it everyday. Each newsletter has a great deal of content and the daily feed allows you to 'pace' yourself. The content is relevant to the areas that I address and the articles are written by counsel who are very experienced in these areas and can communicate in a meaningful and effective way."